– LATVIA, Olaine – JSC Olainfarm (RSE: OLF1R) today announced that in accordance with the plan of its Supervisory Council to further strengthen the management team of the company, Jeroen Weites has been appointed as Chairman of the Management Board, CEO of Olainfarm Group, with 20 years of international experience in the pharmaceutical industry. The former CEO Lauris Macijevskis will remain on the Board of Olainfarm.
Chairman of the Board, CEO of JSC Olainfarm Group Jeroen Weites is entrusted with the overall management and strategic development of the Olainfarm Group as well as new market niche and sales market expansion.
Lauris Macijevskis, Raimonds Terentjevs, Signe Baldere-Sildedze, Milana Beļeviča and Mārtiņš Puriņš remain on the Board of the JSC Olainfarm.
Gundars Bērziņš, Chairman of the Supervisory Council of JSC Olainfarm, said: “We are pleased that management team is joined by such an experienced senior executive with considerable expertise in big pharma management, ensuring the companies’ chosen direction of transformation and the growth of business operating income. Europe is one of the markets where JSC Olainfarm wants to grow while maintaining a solid position in strategically important CIS markets. I am convinced that the addition of such an experienced executive offers real opportunities for the company to develop to a new level. We greatly appreciate the contribution of the current management board under the leadership of L. Macijevskis at such a vital stage for the company and we are delighted he remains on the board. As we move forward, we intend to continue strengthening our management team.”
Chairman of the Board, CEO of JSC Olainfarm Group Jeroen Weites said: “I am delighted to have the opportunity to use my experience in business operations in Europe, CIS and Asia, when joining the Olainfarm team in such a vital stage of development. I have familiarized myself with Olainfarm’s historical success, product portfolios and performance figures, which are all impressive and we must not settle here. Olainfarm has the opportunity to not only become a success story in Latvia but in all the Baltics, where the contribution of every single employee plays a significant role.”
Under the leadership of J. Weites, more than 30 new pharmaceutical products have been successfully introduced in international markets. Jeroen Weites has been the General Manager of Global Healthcare in Sanofi, Bulgaria since 2014, and has led Sanofi’s General Medicine South Europe and North Europe clusters, where his key task was to ensure successful transformation processes for the company. Between 2010 and 2014, he held the position of Senior Director at Sanofi Genzyme, France, primarily responsible for implementing, managing and advising on new European markets as well as developing launch strategies in Japan and China. He also previously held senior positions at UCB Pharma Brussels in Brussels, Belgium and at Biogen Idec in Boston, USA. Weites holds a Master’s degree in Economics from the University of Amsterdam.
About JSC Olainfarm
JSC Olainfarm is one of the largest companies in the Baltic States with more than 45 years of experience in the production of pharmaceuticals and chemical and pharmaceutical products. The basic principle of the company is to produce reliable and effective top quality products for Latvia and the whole world. Currently, JSC Olainfarm products are exported to more than 60 countries worldwide, including the Baltic States, Russia, other CIS countries, Europe, North America, Asia and Australia.
For more information: https://lv.olainfarm.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.